Cart
sales@molnova.com
palovarotene
CAS No. 410528-02-8
palovarotene( RO-3300074 | RO 3300074 | RO3300074 | R-667 )
Catalog No. M17504 CAS No. 410528-02-8
Palovarotene is an agonist of nuclear retinoic acid receptor γ (RAR-γ).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 61 | In Stock |
|
| 10MG | 102 | In Stock |
|
| 25MG | 237 | In Stock |
|
| 50MG | 377 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Namepalovarotene
-
NoteResearch use only, not for human use.
-
Brief DescriptionPalovarotene is an agonist of nuclear retinoic acid receptor γ (RAR-γ).
-
DescriptionPalovarotene, also known as RO-3300074 and R-667, is a highly selective retinoic acid receptor gamma (RAR-γ) agonist that is under investigation as a potential treatment for emphysema. Phase I clinical trials of palovarotene in patients with emphysema demonstrated that the drug is well tolerated, with improvements observed in markers of emphysema progression. Emphysema is characterized by the destruction of alveoli and alveolar ducts within the lungs. Retinoid signaling is believed to play a role in alveologenesis, with the retinoic acid receptor gamma thought to be required for alveolar formation.
-
In Vitro——
-
In Vivo——
-
SynonymsRO-3300074 | RO 3300074 | RO3300074 | R-667
-
PathwayAngiogenesis
-
Targetc-Met/HGFR
-
RecptorRARγ
-
Research AreaOthers-Field
-
Indication——
Chemical Information
-
CAS Number410528-02-8
-
Formula Weight414.55
-
Molecular FormulaC27H30N2O2
-
Purity>98% (HPLC)
-
SolubilityDMSO : 19.5 mg/mL. 47.04 mM;
-
SMILESO=C(O)c1ccc(cc1)/C=C/c3cc4c(cc3Cn2cccn2)C(C)(C)CCC4(C)C
-
Chemical Name4-((1E)-2-(5,5,8,8-Tetramethyl-3-(1H-pyrazol-1-ylmethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)ethenyl)benzoic acid
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Pavey GJ, et al. Targeted stimulation of retinoic acid receptor-γ mitigates the formation of heterotopic ossification in an established blast-related traumatic injury model. Bone. 2016 Sep;90:159-67.
molnova catalog
related products
-
Capmatinib hydrochlo...
Capmatinib hydrochloride is a potent orally active selective and ATP competitive c-Met kinase inhibitor?potently blocking in vitro kinase activity (IC50 = 0.13 nM) as well as constitutive or HGF-stimulated activity in cells (IC50 values range from 0.3 to 1.1 nM).
-
Telisotuzumab
Telisotuzumab(ABT-700) is a humanized recombinant antibody targeting the therapeutic hepatocyte growth factor receptor (MET) with high affinity for c-Met.Telisotuzumab has inhibitory effects on c-Met signaling and antitumor activity.
-
Rilotumumab
Rilotumumab (AMG 102) is a monoclonal antibody targeting hepatocyte growth factor that inhibits HGF/ MET-driven signaling.
